Charles River Laboratories International Shares Outstanding History (CRL)
Charles River Laboratories International reported 49.2M shares outstanding at the end of fiscal 2025.
View full Charles River Laboratories International company overviewCharles River Laboratories International annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-27 | 49.2M | −1.9M | −3.76% |
| 2024 | 2024-12-28 | 51.1M | −197,000 | −0.38% |
| 2023 | 2023-12-30 | 51.3M | 394,000 | +0.77% |
| 2022 | 2022-12-31 | 50.9M | 464,000 | +0.92% |
| 2021 | 2021-12-25 | 50.5M | 713,000 | +1.43% |
| 2020 | 2020-12-26 | 49.8M | 831,000 | +1.70% |
| 2019 | 2019-12-28 | 48.9M | 727,000 | +1.51% |
| 2018 | 2018-12-29 | 48.2M | 807,000 | +1.70% |
| 2017 | 2017-12-30 | 47.4M | 39,000 | +0.08% |
| 2016 | 2016-12-31 | 47.4M | 665,000 | +1.42% |
| 2015 | 2015-12-26 | 46.7M | −629,000 | −1.33% |
| 2014 | 2014-12-27 | 47.3M | −227,000 | −0.48% |
| 2013 | 2013-12-28 | 47.6M | −1.3M | −2.70% |
| 2011 | 2011-12-31 | 48.9M | −7.6M | −13.40% |
| 2010 | 2010-12-25 | 56.4M | −9.4M | −14.32% |
| 2009 | 2009-12-26 | 65.9M | — | — |
Charles River Laboratories International quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-27 | 47.7M | −1.5M | −3.01% |
| Q1 2026 | 2026-03-28 | 48.2M | −948,000 | −1.93% |
| Q4 2025 | 2025-12-27 | 49.2M | −1.9M | −3.76% |
| Q3 2025 | 2025-09-27 | 49.2M | −1.9M | −3.75% |
| Q2 2025 | 2025-06-28 | 49.2M | −2.4M | −4.66% |
| Q1 2025 | 2025-03-29 | 49.1M | −2.4M | −4.65% |
| Q4 2024 | 2024-12-28 | 51.1M | −197,000 | −0.38% |
| Q3 2024 | 2024-09-28 | 51.1M | −162,000 | −0.32% |
| Q2 2024 | 2024-06-29 | 51.6M | 347,000 | +0.68% |
| Q1 2024 | 2024-03-30 | 51.5M | 328,000 | +0.64% |
| Q4 2023 | 2023-12-30 | 51.3M | 394,000 | +0.77% |
| Q3 2023 | 2023-09-30 | 51.3M | 419,000 | +0.82% |
| Q2 2023 | 2023-07-01 | 51.3M | 405,000 | +0.80% |
| Q1 2023 | 2023-04-01 | 51.2M | 382,000 | +0.75% |
| Q4 2022 | 2022-12-31 | 50.9M | 464,000 | +0.92% |
| Q3 2022 | 2022-09-24 | 50.9M | 417,000 | +0.83% |
| Q2 2022 | 2022-06-25 | 50.9M | 470,000 | +0.93% |
| Q1 2022 | 2022-03-26 | 50.8M | 584,000 | +1.16% |
| Q4 2021 | 2021-12-25 | 50.5M | 713,000 | +1.43% |
| Q3 2021 | 2021-09-25 | 50.5M | 724,000 | +1.46% |
| Q2 2021 | 2021-06-26 | 50.4M | 732,000 | +1.47% |
| Q1 2021 | 2021-03-27 | 50.2M | 730,000 | +1.48% |
| Q4 2020 | 2020-12-26 | 49.8M | 831,000 | +1.70% |
| Q3 2020 | 2020-09-26 | 49.7M | 899,000 | +1.84% |
| Q2 2020 | 2020-06-27 | 49.7M | 860,000 | +1.76% |
| Q1 2020 | 2020-03-28 | 49.5M | 739,000 | +1.52% |
| Q4 2019 | 2019-12-28 | 48.9M | 727,000 | +1.51% |
| Q3 2019 | 2019-09-28 | 48.8M | 743,000 | +1.54% |
| Q2 2019 | 2019-06-29 | 48.8M | 798,000 | +1.66% |
| Q1 2019 | 2019-03-30 | 48.7M | 842,000 | +1.76% |
| Q4 2018 · Dec 29 | 2018-12-29 | 48.2M | 807,000 | +1.70% |
| Q3 2018 | 2018-09-29 | 48.1M | 770,000 | +1.63% |
| Q2 2018 | 2018-06-30 | 48.0M | 415,000 | +0.87% |
| Q1 2018 | 2018-03-31 | 47.9M | 270,000 | +0.57% |
| Q4 2017 | 2017-12-30 | 47.4M | 39,000 | +0.08% |
| Q3 2017 | 2017-09-30 | 47.3M | 0 | 0.00% |
| Q2 2017 | 2017-07-01 | 47.6M | 304,000 | +0.64% |
| Q1 2017 | 2017-04-01 | 47.6M | 521,000 | +1.11% |
| Q4 2016 | 2016-12-31 | 47.4M | 665,000 | +1.42% |
| Q3 2016 | 2016-09-24 | 47.3M | 701,000 | +1.50% |
| Q2 2016 | 2016-06-25 | 47.3M | 432,000 | +0.92% |
| Q1 2016 | 2016-03-26 | 47.1M | −241,000 | −0.51% |
| Q4 2015 | 2015-12-26 | 46.7M | −629,000 | −1.33% |
| Q3 2015 | 2015-09-26 | 46.6M | −143,227 | −0.31% |
| Q2 2015 | 2015-06-27 | 46.9M | −49,188 | −0.10% |
| Q1 2015 | 2015-03-28 | 47.4M | −1.0M | −2.09% |
| Q4 2014 | 2014-12-27 | 47.3M | −1.0M | −2.14% |
| Q3 2014 | 2014-09-27 | 46.8M | −787,614 | −1.66% |
| Q2 2014 | 2014-06-28 | 46.9M | −48.21B | −99.90% |
| Q1 2014 · Apr 18 | 2014-04-18 | 48.4M | −48.99B | −99.90% |
| Q1 2014 · Mar 29 | 2014-03-29 | 48.4M | −642,831 | −1.31% |
| Q4 2013 | 2013-12-28 | 47.6M | −1.3M | −2.70% |
| Q3 2013 | 2013-09-28 | 48.25B | 48.20B | +96945.02% |
| Q2 2013 | 2013-06-29 | 49.04B | 48.99B | +95220.50% |
| Q1 2012 | 2012-03-31 | 49.0M | −2.6M | −5.04% |
| Q4 2011 | 2011-12-31 | 48.9M | −7.6M | −13.40% |
| Q3 2011 | 2011-09-24 | 49.7M | −8.0M | −13.84% |
| Q2 2011 | 2011-06-25 | 51.4M | −14.8M | −22.35% |
| Q1 2011 | 2011-03-26 | 51.6M | −14.3M | −21.67% |
| Q4 2010 | 2010-12-25 | 56.4M | — | — |
| Q3 2010 | 2010-09-25 | 57.7M | — | — |
| Q2 2010 | 2010-06-26 | 66.3M | — | — |
| Q4 2009 | 2009-12-26 | 65.9M | — | — |
Charles River Laboratories International shares outstanding trends
Over the last five reported fiscal years, Charles River Laboratories International's shares outstanding moved from 49.8M to 49.2M, a change of −550,000. The latest reported quarter, Q2 2026, shows 47.7M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Charles River Laboratories International filings at SEC.gov ↗